Sphere Medical arterial blood analyser - Proxima Generation 2 - has met its primary endpoint in a multicenter clinical trial.
The primary endpoint showed equivalent performance to laboratory and Point of Care blood gas analysers measuring arterial blood in a clinical setting.
The device has also shown itself resilient to use in the critical care environment including during diathermy.
Proxima Generation 2 draws blood from an arterial line for analysis before flushing to waste which facilitates the near real time analysis, with laboratory accuracy, of a patient’s arterial blood with output data being displayed on a bedside monitor.
Sphere Medical CEO Stuart Hendry said they have demonstrated that Proxima will be able to deliver rapid and convenient measurement of blood chemistry, in a critical care setting without compromising analytical accuracy, equivalent to the current standard of care.
"The information Proxima provides should assist clinicians to enhance patient care and improve outcomes," Hendry said.